Hoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritus
US-based biopharmaceutical company Hoth Therapeutics has reported interim data from a Phase IIa trial of HT-001, a drug designed for…
News
FDA clears eGenesis’ genetically engineered porcine liver for Phase I trial
Accent Therapeutics starts dosing in trial of KIF18A inhibitor for solid tumours
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
Corxel to begin trial of CX11 for obesity with FDA clearance
Neuren confirms Phase III trial goals for PMS drug NNZ-2591
Pheast treats first subject in Phase I trial of advanced solid tumour therapy
